Exidavnemab

N/A

Report date: 2025/03/18 10:36:38

Base Information

Drug NameExidavnemab
Drug Alias NamePD-0805BAN-0805BBV-0805ABBV-0805PR-1808164
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionSynuclein alpha inhibitors
TargetsSynuclein alpha
Therapy Area/IndicationsParkinson DiseaseMultiple System Atrophy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandPuerto Rico +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBioarctic Ab
China Registration ClassN/A

Develop Information

Active CompaniesBioarctic Ab
Inactive CompaniesAbbvie Inc
Active IndicationsParkinson DiseaseMultiple System Atrophy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A